A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients (Q41197125)

28 September 2017

A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients (English)

1 reference

28 September 2017

acute myeloid leukemia

1 reference

Ya-Ping Chen

9

0 references

Jorge Eduardo Cortes

15

object named as

Jorge Cortes

1 reference

28 September 2017

4

Gautam Borthakur

1 reference

28 September 2017

7

Elias Jabbour

1 reference

28 September 2017

6

Naveen Pemmaraju

1 reference

28 September 2017

Hui-Jen Tsai

1

1 reference

28 September 2017

Shih Sheng Jiang

2

1 reference

28 September 2017

Wen-Chun Hung

3

1 reference

28 September 2017

Sheng-Fung Lin

5

1 reference

28 September 2017

John S Bomalaski

8

1 reference

28 September 2017

Hui-Hua Hsiao

10

1 reference

28 September 2017

Ming-Chung Wang

11

1 reference

28 September 2017

Ching-Yuan Kuo

12

1 reference

28 September 2017

Hung Chang

13

1 reference

28 September 2017

Su-Peng Yeh

14

1 reference

28 September 2017

Li-Tzong Chen

16

1 reference

28 September 2017

Tsai-Yun Chen

17

1 reference

28 September 2017

language of work or name

English

0 references

publication date

12 September 2017

1 reference

28 September 2017

1 reference

28 September 2017

7

1 reference

28 September 2017

1

1 reference

28 September 2017

11253

1 reference

Creative Commons Attribution 4.0 International

28 September 2017

start time

12 September 2017

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Arginine dependence of tumor cells: targeting a chink in cancer's armor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5595917

28 September 2017

Acute Myeloid Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5595917

Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5595917

Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5595917

Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5595917

TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5595917

Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5595917

Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5595917

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5595917

Fast gapped-read alignment with Bowtie 2

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5595917

A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5595917

A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5595917

A method and server for predicting damaging missense mutations

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5595917

Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5595917

Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5595917

Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5595917

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5595917

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5595917

Constitutive activation of STAT5A promotes human hematopoietic stem cell self-renewal and erythroid differentiation

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5595917

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5595917

Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5595917

The generation of energy by the arginine dihydrolase pathway in Mycoplasma hominis 07.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5595917

Arginine addiction in AML.

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5595917

Metabolic response to pegylated arginine deiminase in mesothelioma with promoter methylation of argininosuccinate synthetase

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5595917

Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5595917

Global gene expression profile of human cord blood-derived CD133 cells

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5595917

Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo

19 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5595917

Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization f

19 August 2018

1 reference

https://api.crossref.org/works/10.1038/S41598-017-10542-4

7 January 2021

Non-infusional vs intravenous consolidation chemotherapy in elderly patients with acute myeloid leukemia: final results of the EORTC-GIMEMA AML-13 randomized phase III trial

1 reference

https://api.crossref.org/works/10.1038/S41598-017-10542-4

7 January 2021

Growth response of stable and primary cell cultures to L-ornithine, L-citrulline, and L-arginine

1 reference

https://api.crossref.org/works/10.1038/S41598-017-10542-4

7 January 2021

Studies on neutralization of L-asparaginase activity in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038/S41598-017-10542-4

7 January 2021

Hypersensitivity reactions to biological drugs

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28900115

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1038/S41598-017-10542-4

1 reference

28 September 2017

1 reference

28 September 2017

PubMed publication ID

28900115

1 reference